Client Header Links

Clinical Trials
Clinical Trials
Clinical Trials
Clinical Trials
Careers
Contacts

Investors

News

Keyword Search

Year

Apr 06, 2022

CTI BioPharma to Present at the 21st Annual Needham Virtual Healthcare Conference

SEATTLE , April 6, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference at 1:30 p.m. ET . The conference will be held in a virtual meeting format.

Mar 31, 2022

CTI BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results

– VONJO TM (pacritinib) Approved by FDA for the Treatment of Adult Myelofibrosis Patients with Myelofibrosis and Thrombocytopenia; Commercial Launch Underway – – $60 Million Payment from DRI Healthcare Trust Triggered by FDA Approval under the Terms of the Previously Announced Debt and Royalty

Mar 02, 2022

CTI BioPharma to Present at the Cowen 42nd Annual Healthcare Conference

SEATTLE , March 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen Annual Healthcare Conference at 1:30 p.m. ET . The conference will be held in a virtual meeting format.

Feb 28, 2022

CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

- VONJO is the First Approved Therapy to Specifically Address the Needs of Adult Cytopenic Myelofibrosis Patients - - NDA Approved Under Priority Review - - Approval Triggers $60 Million Payment from DRI Healthcare Trust - - CTI to Host Conference Call Tomorrow at 8:00 a.m. ET - SEATTLE , Feb.

Feb 18, 2022

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , Feb. 18, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated

Jan 06, 2022

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , Jan. 6, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated

Pagination

First page
Previous page
Page 1
Current page 2

Shareholder Tools

print page
email page
RSS Feed
Email Alerts
IR Contacts

Site - Investor Relations

Corporate Profile
Press Releases
Events & Presentations
- Events
- Investor Presentation
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Financial Information
Corporate Governance
Resources

–

3101 Western Ave., #800
Seattle, WA 98121
U.S.A.

–

T +1 206-282-7100
T +1 800-215-2355 (US only)
F +1 206-284-6206